News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Nancy L. Reaven, MA

Articles by Nancy L. Reaven, MA

All-Cause Costs Increase Exponentially with Increased Chronic Kidney Disease Stage

ByLadan Golestaneh, MD, MS,Paula J. Alvarez, RPh, MPH, MBA,Nancy L. Reaven, MA,Susan E. Funk, MBA, FACHE,Karen J. McGaughey, PhD,Alain Romero, PhD,Melanie S. Brenner, PharmD, BCPS,Macaulay Onuigbo, MD, MSc, MBA

June 21st 2017

Evaluation of Clinical Outcomes and Costs Based on Prescribed Dose Level of Renin-Angiotensin-Aldosterone System Inhibitors

ByMurray Epstein, MD,Paula J. Alvarez, RPh, MPH, MBA,Nancy L. Reaven, MA,Susan E. Funk, MBA, FACHE,Karen J. McGaughey, PhD,Melanie S. Brenner, PharmD, BCPS,Wade Benton, PharmD,Ladan Golestane

August 31st 2016

Evaluation of the Treatment Gap Between Clinical Guidelines and the Utilization of Renin-Angiotensin-Aldosterone System Inhibitors

ByMurray Epstein, MD,Nancy L. Reaven, MA,Susan E. Funk, MBA,Karen J. McGaughey, PhD,Nina Oestreicher, PhD,John Knispel, MD

September 16th 2015

Latest Updated Articles

Evaluation of the Treatment Gap Between Clinical Guidelines and the Utilization of Renin-Angiotensin-Aldosterone System Inhibitors
Published: September 16th 2015 | Updated:
Evaluation of Clinical Outcomes and Costs Based on Prescribed Dose Level of Renin-Angiotensin-Aldosterone System Inhibitors
Published: August 31st 2016 | Updated:
All-Cause Costs Increase Exponentially with Increased Chronic Kidney Disease Stage
Published: June 21st 2017 | Updated:

Trending on AJMC

Government Shutdown Concluded but ACA Subsidies in Limbo

Can a Coffee a Day Keep AFib Away?

FDA Approves Ziftomenib for R/R NPM1-Mutated AML

How MS Treatment Strategies Are Evolving: Rebecca Spain, MD

High BMI Drives Worldwide Surge in Ovarian, Uterine Cancer Cases

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.